Therapeutic Uses of Beta-Blockers in Psychosomatics

  • A. N. Singh


The present status and future prospect of beta-blockers in clinical psychiatry remain provocatingly controversial but stimulating enough to warrant the review of the available literature for ever expanding therapeutic applications. Psychiatrists in recent years have been exploring the therapeutic uses of beta-blockers in the management of (1) Anxiety Neurosis, (2) temporary life stress situation, (3) Lithium induced tremor, (4) alcoholic withdrawal syndrome, (5) opiate withdrawal, (6) for control of aggression and rage, and (7) schizophrenia.


Orientate Response Alcoholic Withdrawal Syndrome Opiate Withdrawal Opiate Addict Anxiety Neurosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenblatt, D., Shaker, R. On the psychopharmacology of beta-blockade. Curr. Ther. Res. 14: 615–625, 1972.PubMedGoogle Scholar
  2. 2.
    Granville-Grossman, K.L., Turner, P. The effect of propranolol on anxiety. Lancet 1: 788–790, 1966.PubMedCrossRefGoogle Scholar
  3. 3.
    Kellner, R., Collins, A.C., Shulman, R.S. The short-term anti-anxiety effects of propranolol Hcl. J. Clin. Pharmacol. 14: 301–304, 1974.PubMedGoogle Scholar
  4. 4.
    Tanna, V., Penningroth, R., Wollson, R. Propranolol in the treatment of anxiety neurosis. Comp. Psychiat. 18: 319–326, 1977.CrossRefGoogle Scholar
  5. 5.
    Bonn, J.A., Turner, P. D-propranolol and anxiety. Lancet 1: 1355–1356, 1971.PubMedCrossRefGoogle Scholar
  6. 6.
    Burrows, G., Davies, B., Fail, L. A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 50: 177–179, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnson, G., Singh, B., Leeman, M. Controlled evaluation of the beta adrenorecptor blocking drug oxprenolol in anxiety. Med. J. Australia 1: 909–912, 1976.Google Scholar
  8. 8.
    Suzman, M.M. The use of beta-adrenergic blockage with propranolol in anxiety states. Postgrad. Med. J. 47: 104–108, 1971.Google Scholar
  9. 9.
    Becker, A.L. Oxprenolol and propranolol in anxiety states: a double-blind comparative study. So. African Med. J. 50: 627629, 1976.Google Scholar
  10. 10.
    Suzman, M.M. Propranolol in the treatment of anxiety. Postgrad. Med. J. 52 (Suppl. 4): 168–174, 1976.Google Scholar
  11. 11.
    Tyrer, P.J., Lader, M.H. Effects of beta adrenergic blockade with sotalol in chronic anxiety. Clin. Pharmacol. Ther. 14: 418–426, 1973.PubMedGoogle Scholar
  12. 12.
    Easton, J.D., Sherman, D. Somatic anxiety attacks and propranolol. Arch. Neurol. 33: 689–691, 1976.Google Scholar
  13. 13.
    Bonn, J.A., Turner, P., Hicks, D.C. Beta-adrenergic receptor blockade with practolol in treatment of anxiety. Lancet 1: 814–815, 1972.PubMedCrossRefGoogle Scholar
  14. 14.
    Tyrer, P.J., Lader, M.H. Response to propranolol and diazepam in somatic and psychic anxiety. Br. Med. J. 2: 14–16, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Singh, A.M. Clinical experiences with beta-blockers in psychiatry. Symp. of Beta-blockers in cardiology and psychiatry. O.M.A. Annual Mtg., 1980 (in press).Google Scholar
  16. 16.
    Hawkings, J. Clinical experience with beta-blockers in consultant psychiatric practice. Scottish Med. J. 20: 294–298, 1975.Google Scholar
  17. 17.
    Brewer, C. Beneficial effect of beta-adrenergic blockade on “exam nerves.” Lancet 2: 435, 1972.PubMedCrossRefGoogle Scholar
  18. 18.
    Krishnan, G. Oxprenolol in the treatment of examination nerves. Scottish Med. J. 20: 288–289, 1975.Google Scholar
  19. 19.
    James, I., Pearson, R., Griffith, D. Effect of oxprenolol on stage-fright in musicians. Lancet 2: 952–954, 1977.PubMedCrossRefGoogle Scholar
  20. 20.
    Kirk, L. Baastrup, P.C., Schou, M. Propranolol and lithium-induced tremor. Lancet 1972/I,839; corresp.Google Scholar
  21. 21.
    Floru, L. Klinische Behandlungsversuche des lithiumbedingten Tremors durch einen B-Rezeptorenantagonisten (Propranolol). Int. Pharmacopsychiat. 6, 197 (1971).Google Scholar
  22. 22.
    Kirk, L.,Baastrup, P.C., Schou, M. Propranolol treatment of lithium-induced tremor. Lancet 1973 (II, 1086: corresp.)Google Scholar
  23. 23.
    Kirk, L., Baastrup, P.C., Schou, M. Propranololbehandlung bei Lithium tremor. Nervenarzt 44, 657, 1973.PubMedGoogle Scholar
  24. 24.
    Rafaelson, O. Discussion. In Kielholz, P. (Ed): Beta-blockers and the Central Nervous System. Baltimore, Univ. Park Press, 1976, pp. 231–234.Google Scholar
  25. 25.
    Freedman, A. Beta-blockers in the treatment of alcoholism and opiate addiction. In Kielholz, P. (Ed): Beta-blockers and the Central Nervous System, Baltimore, Univ. Park Press, 1976, pp. 141–148.Google Scholar
  26. 26.
    Carlsson, C. Haemodynamic effects of adrenergic beta-receptor blockade in the withdrawal phase of alcoholism. Internat. J. Clin. Pharmacol. 3: 61–63, 1969.Google Scholar
  27. 27.
    Carlsson, C., Johansson, T. The psychological effects of propranolol in the abstinence phase of chronic alcoholics. Br. J. Psychiat. 119: 605–606, 1971.CrossRefGoogle Scholar
  28. 28.
    Sellers, E., Zilm D., Degani, N. Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. J. Studies Alcohol 38: 2096–2108, 1977.Google Scholar
  29. 29.
    Gunne, L.M. Catecholamines and 5-hydroxytryptamine in morphine tolerance and withdrawal. Acta physiol. scand. 58, Suppl. 204, 1963.Google Scholar
  30. 30.
    Grosz, H.J. Effect of propranolol on active users of heroin. Lancet 1973/II,612.Google Scholar
  31. 31.
    Hollister, L.E., Prusmack, J.J. Propranolol in withdrawal from opiates. Arch. gen. Psychiat. 31, 695, 1974.PubMedCrossRefGoogle Scholar
  32. 32.
    Ressnick, R.B., Kestenbaum, R.S., Schwartz, L.K., Smith, A. Evaluation of propranolol in opiate dependence. Arch. gen. Psychiat. 33, 993, 1976.CrossRefGoogle Scholar
  33. 33.
    Elliott, F.A. Ann Neurol 1: 489–491, 1977.PubMedCrossRefGoogle Scholar
  34. 34.
    Yudofsky, S. Am. J. Psychiatry 108, 218–220, 1981.Google Scholar
  35. 35.
    Petrie, M.M., Ban, T.A. Lancet 1: 325, 1981.Google Scholar
  36. 36.
    Manshein, P. J. Clin. Psychiatry 42: 132, 1981.Google Scholar
  37. 37.
    Shevitz. J. Nerv. Ment. Dis. 168: 246–48, 1980.CrossRefGoogle Scholar
  38. 38.
    Schreier, H.A. Am. J. Psychiatry 136: 840–41.Google Scholar
  39. 39.
    Yorkston, N., Zaki, S., Havard, C. Some practical espects of using propranolol in the treatment of schizophrenia. In Robert E. Amacher, P. (Eds): Propranolol and Schizophrenia, New York, Liss, 1978, pp. 83–97.Google Scholar
  40. 40.
    Atsom, A., Blum, I., Wijsenbeek, H. The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Psychiat. Neurol. Neurochir. 74: 251–258, 1971.Google Scholar
  41. 41.
    Atsmon, A., Blum, I. The discovery. In Roberts, E., Amacher, P. (Eds): Propranolol and Schizophrenia, New York, Liss, 1978, pp. 5–38.Google Scholar
  42. 42.
    Yorkston, N., Zaki, S., Malik, M. Propranolol in the control of schizophrenic symptoms. Br. Med. J. 4: 633–635, 1974.PubMedCrossRefGoogle Scholar
  43. 43.
    Yorkston, N., Zaki, S., Havard, C. Propranolol in the treatment of schizophrenia; an uncontrolled study with 55 adults. In Roberts, E., Amacher, P. (Eds): Propranolol and Schizophrenia, New York, Liss, 1978, pp. 39–67.Google Scholar
  44. 44.
    Yorkston, N., Zaki, S., Themen, J. Safeguards in the treatment of schizophrenia with propranolol. Postgrad. Med. J. 52 (Suppl. 4): 175–180, 1976.PubMedGoogle Scholar
  45. 45.
    Yorkston, N., Gruzelier, J., Zaki, S. Propranolol as an adjunct to the treatment of schizophrenia. In Roberts, E., Amacher, P. (Eds): Propranolol and Schizophrenia. New York, Liss, 1978, pp. 69–82.Google Scholar
  46. 46.
    Volk, W., Bier, W., Braun, J. Treatment of excited psychosis with a beta-blocker receptor (oxprenolol) in high dosages. Nervenartzt 43: 491–492, 1972.Google Scholar
  47. 47.
    Hanssen, T., Heyden, T., Sundberg, I. Propranolol in Schizophrenia. Arch. Gen. Psychiatry, 1980, 37: 685–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Lindstorm, I.H., Persson, E. Propranolol in chronic Schizophrenia; a controlled study in neuroleptic treated patients. Br. J. Psychiat., 1980, 137: 126–30.CrossRefGoogle Scholar
  49. 49.
    Gardos, G., Cole, J., Volicer, L. A dose-response study of propranolol in schizophrenics. Curr. Ther. Res. 15: 314–323, 1973.PubMedGoogle Scholar
  50. 50.
    Rackensperger, W., Gauppe, R., Mattke, D. Treatment of acute Schizophrenic psychoses with beta-receptor blockers. Arch. Psychiat. Nervenkrank 219: 29–36, 1974.CrossRefGoogle Scholar
  51. 51.
    Gruzelier, J., Thronton, S., Stanforth, S. Active and passive avoidence barring on racemic propranolol and neuroleptics. Br. J. Psychiat., 1980, 137: 131–37.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • A. N. Singh
    • 1
  1. 1.Hamilton Psychiatric HospitalHamiltonCanada

Personalised recommendations